<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04761965</url>
  </required_header>
  <id_info>
    <org_study_id>NCPHOI-2019-06</org_study_id>
    <nct_id>NCT04761965</nct_id>
  </id_info>
  <brief_title>Quantitative MRI of Bone Marrow Fat Fraction in Patients With Trepanobiopsy</brief_title>
  <official_title>Clinical Study of the Sensitivity and Specificity of the Quantitative Assessment of Bone Marrow Cellularity by MRI in Comparison With Trepanobiopsies in Patients With Diseases of the Hematopoietic System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to find correlation between the assessment of cellularity according to&#xD;
      trepanobiopsy data and the results of measuring MRI parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ratio of fat to water in the bone marrow depends on the cellularity of the bone marrow.&#xD;
      In addition to the water/fat ratio in bone marrow there are also other parameters for&#xD;
      quantitative MRI assessment. These include the apparent diffusion coefficient (ACD), the T1&#xD;
      relaxation time, mapping of the macromolecular proton fraction. The undoubted advantage of&#xD;
      MRI is its non-invasiveness and the ability to assess any localization of the bone marrow.&#xD;
&#xD;
      MRI may become a new non-invasive method for assessing the cellularity of the bone marrow in&#xD;
      children with oncohematological diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 16, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 26, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>correlation between Bone marrow cellularity by mDixon-quant and trepanobiopsy.</measure>
    <time_frame>Before the start of treatment</time_frame>
    <description>Determination of bone marrow cellularity before starting therapy for the underlying disease. Cellularity according to trepanobiopsy data is the ratio of stromal and hematopoietic cells to fat cells in the bone marrow. Cellularity according to MRI - the ratio of water and fat in the bone marrow using the mDixom Quant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T1 maping</measure>
    <time_frame>Before the start of treatment</time_frame>
    <description>T1 mapping (ms) is a magnetic resonance imaging technique used to calculate the T1 time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent diffusion coefficient</measure>
    <time_frame>Before the start of treatment</time_frame>
    <description>value of apparent diffusion coefficient in mm2/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the macromolecular proton fraction (MPF)</measure>
    <time_frame>Before the start of treatment</time_frame>
    <description>Percentage of the macromolecular proton fraction (MPF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the bone marrow fat fraction</measure>
    <time_frame>Before the start of treatment</time_frame>
    <description>Percentage of the bone marrow fat fraction (FF) by spectroscopy</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Aplastic Anemia</condition>
  <condition>Aplastic Anemia Idiopathic</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Bone marrow cellularity by mDixon-quant</intervention_name>
    <description>if trepanobiopsy was performed during the diagnosis, then comparison with MRI Bone marrow cellularity by mDixon-quant</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        presence of indications for performing trepanobiopsy:&#xD;
&#xD;
          1. aplastic anemia&#xD;
&#xD;
          2. chronic myeloproliferative disease&#xD;
&#xD;
          3. reactive changes in hematopoiesis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refusal to sign an informed consent to participate in a clinical trial&#xD;
&#xD;
          2. Presence of contraindications for MRI examination&#xD;
&#xD;
          3. Extremely serious condition of the patient at the time of inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nataliia Kriventsova</last_name>
    <phone>+7 (495)2876570</phone>
    <phone_ext>4508</phone_ext>
    <email>nataliya.krivencova@fccho-moscow.ru</email>
  </overall_contact>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 20, 2021</last_update_submitted>
  <last_update_submitted_qc>February 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quantitative MRI</keyword>
  <keyword>trepanobiopsy</keyword>
  <keyword>Aplastic Anemia Idiopathic</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

